Dear Editor:

It has been extensively documented that osteoprotegerin (OPG), a soluble member of the TNF receptor superfamily, inhibits osteoclastogenesis by binding to receptor activator of NF-kB ligand (RANKL) and preventing interaction with its cognate transmembrane receptor RANK \[reviewed in [@b1]\]. However, OPG can also interact with, and neutralize, TNF-related apoptosis inducing ligand (TRAIL), whose extracellular domain shares a 30% homology with the extracellular domain of RANKL \[reviewed in [@b2]\]. Although some inconsistencies on the differential binding affinity of OPG for RANKL *versus* TRAIL were present in initial studies \[[@b2]\], it has been recently demonstrated that the affinity of native OPG for native TRAIL is comparable to that for RANKL (45 nM *versus* 23 nM, respectively) at 37°C, as determined by plasmon surface resonance analysis \[[@b4]\]. Consistently with this biochemical study, OPG has been shown to act in a paracrine and autocrine manner by binding TRAIL and promoting the survival of multiple myeloma \[[@b5]\], prostate cancer \[[@b6]\], ameloblastoma cells \[[@b7]\] and synovial fibroblasts \[[@b8]\]. Interestingly, previous data from different groups have shown that recombinant TRAIL modulates the differentiation of erythroid and myeloid precursors \[[@b9]\], while inhibits both human and mouse osteoclastogenesis when added to pre-osteoclast cultures induced to differentiate with recombinant macrophage colony-stimulating factor (M-CSF) +RANKL as well as to mature osteoclasts \[[@b11]\]. On the other hand, a couple of studies suggested that recombinant soluble TRAIL might promote osteoclastogenesis \[[@b4]\], and the proposed molecular mechanism to explain such observation was a competition between TRAIL and RANKL for OPG binding. However, it should be noticed that Vitovsky *et al.* used much higher concentrations of TRAIL (500 ng/ml) than RANKL (30 ng/ml) or OPG (50 ng/ml) and more importantly used mouse bone marrow pre-osteoclasts \[[@b4]\]. In this respect, it has been clearly shown that mouse pre-osteoclasts only express TRAIL-R2 \[[@b2]\], while human peripheral blood-derived pre-osteoclasts express both death receptors TRAIL-R1 and TRAIL-R2 as well as TRAIL-R4 \[[@b11]\].

Therefore, to further elucidate the important issue of the interplay between RANKL, TRAIL and OPG in human osteoclastogenesis, we have cultured adherent PBMC with M-CSF+RANKL for 14 days in the absence or presence of recombinant OPG and recombinant TRAIL, prepared as previously described \[[@b16]\]. TRAIL and OPG were added alone or in combination. Importantly, all cytokines were used at the same concentration (50 ng/ml). As expected \[[@b11]\], the addition of TRAIL to M-CSF+RANKL significantly (*P* \< 0.05) inhibited osteoclast formation ([Fig. 1A and B](#fig01){ref-type="fig"}). Of note, recombinant OPG completely abrograted (*P* \< 0.05) osteoclast formation irrespectively of the presence of recombinant TRAIL in culture ([Fig. 1A and B](#fig01){ref-type="fig"}). The anti-osteoclastic activity of OPG could not be ascribed to a low affinity of OPG for TRAIL since OPG (50 ng/ml) efficiently inhibited the apoptosis induced by TRAIL (50 ng/ml) in HL-60 leukemic cells (data not shown).

![Effect of combined treatment of RANKL, TRAIL and OPG on osteoclastic differentiation. Adherent PBMC were cultured with M-CSF alone for 6 days. Then cells were cultured for additional 14 days with the addition of RANKL in the absence or presence of TRAIL and/or OPG, as indicated. Cultures were analysed for osteoclastic differentiation by scoring the number of TRAP^+^ multinucleated cells (**A**), and measuring the levels of TRAP 5b (**B**), a specific marker of resorption activity, in culture supernatants by ELISA. Data represent the means ±SD of three different experiments performed in duplicate.](jcmm0012-1063-f1){#fig01}

Our current observations on one hand confirm that TRAIL has anti-osteoclastic activity and on the other hand indicate that it does not affect the potent anti-osteoclastic activity of OPG at least in the simplified model of osteoclastogenesis represented by human PBMC induced to differentiate by M-CSF+RANKL. Taken together with previous studies \[[@b4]\], these data also suggest that the relative concentrations of TRAIL, RANKL and OPG in the local microenvironment are likely key determinant for the regulation of osteoclastogenesis.
